...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>IJC Heart & Vasculature >Double Jeopardy: Will the new trials tell us how to manage patients with atrial fibrillation and coronary artery disease?
【24h】

Double Jeopardy: Will the new trials tell us how to manage patients with atrial fibrillation and coronary artery disease?

机译：双重危险：新试验能否告诉我们如何治疗房颤和冠心病患者？

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Atrial fibrillation (AF) is a common arrhythmia disorder associated with increased morbidity and mortality, primarily driven by myocardial ischemia, heart failure and stroke. Present therapy with antiarrhythmic drugs is still unsatisfactory and stroke prevention with anticoagulants require careful consideration of concomitant bleeding risks [1,2]. Pa- tients afflicted with AF are burdened with a vastly increased risk of thromboembolism and ischemic stroke, particularly those with coro- nary artery disease (CAD). The complex relationship between AF and thrombotic risk remains poorly understood. A state of AF can drive a procoagulant platelet phenotype, but aberrant platelet activation is not consistently observed in patients with AF; moreover, the IMPACT trial demonstrated there is no clear temporal association between AF and stroke [3]. The best management of patients with AF and CAD is therefore a matter of controversy and a weighing-up of individual risks and benefits.
机译：心房颤动（AF）是一种常见的心律不齐疾病，与发病率和死亡率增加有关，主要由心肌缺血，心力衰竭和中风引起。目前使用抗心律失常药物的治疗仍不能令人满意，使用抗凝剂预防中风需要仔细考虑伴随的出血风险[1,2]。患有房颤的患者的血栓栓塞和缺血性中风的风险大大增加，尤其是那些患有冠状动脉疾病（CAD）的患者。房颤与血栓形成风险之间的复杂关系仍然知之甚少。 AF状态可以驱动血小板凝结表型，但是在AF患者中并不能始终观察到异常的血小板活化。此外，IMPACT试验证明房颤和中风之间没有明显的时间关联[3]。因此，对AF和CAD患者的最佳治疗是一个有争议的问题，并且要权衡个人的风险和利益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号